Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on GoodRx Holdings (GDRX – Research Report), Petiq (PETQ – Research Report) and Biodesix (BDSX – Research Report).
GoodRx Holdings (GDRX)
Bank of America Securities analyst Allen Lutz maintained a Sell rating on GoodRx Holdings today and set a price target of $5.00. The company’s shares closed last Wednesday at $7.61.
According to TipRanks.com, Lutz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for GoodRx Holdings with a $8.88 average price target.
See the top stocks recommended by analysts >>
Petiq (PETQ)
In a report released today, Ryan Meyers from Lake Street reiterated a Buy rating on Petiq, with a price target of $28.00. The company’s shares closed last Wednesday at $17.65.
According to TipRanks.com, Meyers is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Petiq with a $26.08 average price target.
Biodesix (BDSX)
In a report released today, Thomas Flaten from Lake Street reiterated a Buy rating on Biodesix, with a price target of $3.00. The company’s shares closed last Wednesday at $1.55.
According to TipRanks.com, Flaten ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Biodesix is a Moderate Buy with an average price target of $3.25, an 116.7% upside from current levels. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $3.50 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GDRX:
- Investors in GoodRx Holdings, Inc. Should Contact Levi & Korsinsky LLP Before June 21, 2024 to Discuss Your Rights – GDRX
- Yum! downgraded, Cava upgraded: Wall Street’s top analyst calls
- GoodRx upgraded to Overweight from Sector Weight at KeyBanc
- GoodRx files to sell 99.98M shares of Class A common stock for holders
- ‘Time to Hit Buy,’ Says Wells Fargo About These 2 Stocks
